Bill And Melinda Gates Foundation Bill And Melinda Gates Foundation [Member] Bill And Melinda Gates Foundation [Member] Supplemental disclosure of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Right of use asset Operating Lease, Right-of-Use Asset Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Legal, accounting and other fees related to purchase agreement Deferred Offering Costs Income Statement Location Income Statement Location [Axis] Statistical Measurement Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Annual maintenance fee Cost, Maintenance Additional paid-in capital Additional Paid in Capital, Common Stock Entity Filer Category Entity Filer Category Canceled/forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Additional potential grant funding Additional Potential Funding Related To Grant Award Additional Potential Funding Related To Grant Award Other non-current assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Amended and Restated Two Thousand Fourteen Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Milestone payment paid in common stock Milestone Payments, Contingent Amount Milestone payments, contingent amount. Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Business development Business Development Hammock Pharmaceuticals, Inc Hammock Pharmaceuticals, Inc. [Member] Hammock Pharmaceuticals, Inc. [Member] Document Fiscal Year Focus Document Fiscal Year Focus Subsequent Event Type Subsequent Event Type [Domain] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Proceeds from the exercise of stock options Proceeds from Issuance or Sale of Equity Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development Research and Development Expense [Member] Sale of Stock Sale of Stock [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Business Acquisition Business Acquisition [Axis] Potential annual license maintenance fee, payments in year one Potential Annual License Maintenance Fee, Payments In Year One Potential Annual License Maintenance Fee, Payments In Year One Equity Award Award Type [Domain] Assets Assets [Abstract] Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Settlement of contingent closing consideration liability with stock issuance in connection with acquisition of business Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability Noncash or Part Noncash Acquisition, Common Stock Issued for Settlement of Contingent Consideration Liability Cash and cash equivalents Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued Stock options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Entity Address, City or Town Entity Address, City or Town Accumulated deficit Retained Earnings [Member] Regular purchase, common stock issuable (in shares) Regular Repurchase, Common Stock Issuable Regular Repurchase, Common Stock Issuable Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Project [Domain] Project [Domain] Related Party Related Party [Axis] Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Warrants Expiring on December 1, 2021 Warrants Expiring On December One Two Thousand Twenty One [Member] Warrants expiring on december one two thousand twenty one. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Entity Interactive Data Current Entity Interactive Data Current Number of operating segments Number of Operating Segments Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Loss per common share - basic (in usd per share) Earnings Per Share, Basic Contingent consideration Business Combination, Contingent Consideration, Liability, Current Unamortized stock-based compensation expense Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Document Type Document Type Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Grant, DARE-FRT1 Grant, DARE-FRT1 [Member] Grant, DARE-FRT1 Prepaid expenses Prepaid Expense, Current Deemed dividend from trigger of down round provision feature Deemed dividend from trigger of down round provision feature Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount Total payment Research and Development Agreement, Commitment, Amount Research and Development Agreement, Commitment, Amount Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock And Warrants Net proceeds from issuance of common stock and warrants. Entity Current Reporting Status Entity Current Reporting Status Cash paid for measurement of operating lease liabilities Operating Lease, Payments Options to purchase number of outstanding shares of common stock (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Liability, Noncurrent Warrants Expiring on December 6, 2021 Warrants Expiring On December Six Two Thousand Twenty One [Member] Warrants expiring on december six two thousand twenty one. Commission percent Percentage Of Aggregate Commission Percentage of aggregate commission. Potential additional consideration payable Registration Payment Arrangement, Maximum Potential Consideration Plan Name Plan Name [Axis] CRADA CRADA [Member] CRADA Level 1 Fair Value, Inputs, Level 1 [Member] Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Document Transition Report Document Transition Report Total liabilities and stockholders' equity (deficit) Liabilities and Equity Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Commitments and Contingencies Commitments Disclosure [Text Block] Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Liabilities and stockholders’ equity (deficit) Liabilities and Equity [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Net Loss Per Share Earnings Per Share [Text Block] Operating expenses Operating Expenses [Abstract] ATM Sales Agreement At The Market Sales Agreement [Member] At The Market Sales Agreement [Member] Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-cash loss on settlement of contingent liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Balance Sheet Location [Domain] Balance Sheet Location [Domain] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Square footage of office space Net Rentable Area Proceeds from issuance of note payable Proceeds from Notes Payable Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Class of Warrant or Right Class of Warrant or Right [Domain] Trading Symbol Trading Symbol License agreement termination period due to performance failure License Agreement Termination Period Due To Performance Failure License agreement, termination period due to performance failure. Current liabilities Liabilities, Current [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Certain clinical and regulatory development milestone payments, term Research And Development Milestone Payment, Term Research And Development Milestone Payment, Term General and administrative General and Administrative Expense Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Exercisable (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock-Based Compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Offering expenses Payments of Stock Issuance Costs Issuance of common stock, net of issuance costs (in shares) Common stock, shares issued and sold (in shares) Stock Issued During Period, Shares, New Issues Total operating lease liabilities Operating Lease, Liability Warrants Expiring on April 4, 2026 Warrants Expiring On April Four Two Thousand Twenty Six [Member] Warrants expiring on april four two thousand twenty six. Common stock, $0.0001 par value; 120,000,000 shares authorized; 76,601,624 and 41,596,253 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively Issues shares Common Stock, Value, Issued Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies (Note 7) Commitments and Contingencies Subsequent Event [Table] Subsequent Event [Table] Leased Properties Lessee, Operating Leases [Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Remainder of 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Receivables [Abstract] Receivables [Abstract] Accounting Standards Update 2017-11 Accounting Standards Update 2017-11 [Member] Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Working capital Working Capital Increase (Deficit) Working Capital Increase (Deficit) Document Period End Date Document Period End Date Class of Stock [Axis] Class of Stock [Axis] Entity Registrant Name Entity Registrant Name Offering expenses Offering Expenses Offering Expenses Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Shares underlying outstanding warrants (in shares) Class of Warrant or Right, Outstanding Loan under paycheck protection program Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Less: accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Common stock issued to microchips capital stock holders (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Accrued expenses Accrued Liabilities, Current 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Revenue from grant for notice of award Revenue from Contract with Customer, Excluding Assessed Tax Other cost Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Employee Stock Option Stock options Share-based Payment Arrangement, Option [Member] Prepaid expenses Increase (Decrease) in Prepaid Expense Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Weighted average amortization period Weighted Average Amortization Period Weighted Average Amortization Period Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Common stock Common Stock [Member] Loss from operations Operating Income (Loss) Current portion of lease liabilities Operating Lease, Liability, Current License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member] Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Additional paid-in capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation Depreciation Upon Delivery of Six Month Batch Development Not Later Than Eleven Months Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Accrued expenses Increase (Decrease) in Accrued Liabilities Milestone payments Research And Development Milestone Payment Research and development milestone payment. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Warrants to purchase common stock exercised (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Deferred grant funding Deferred Grant Funding Current Deferred Grant Funding Current Other income (expense) Other Nonoperating Income (Expense) Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Issuance cost on equity line paid in common stock (in shares) Stock Issued During Period, Shares, Consideration For Commitment To Purchase Shares Stock Issued During Period, Shares, Consideration For Commitment To Purchase Shares Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Legal Entity Legal Entity [Axis] Initial payment Grants Receivable Award Type Award Type [Axis] Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total stockholders' equity (deficit) Beginning balance Ending balance Stockholders' Equity Attributable to Parent Health Care Trust Funds [Domain] Health Care Trust Funds [Domain] Health Care Trust Funds [Domain] Common stock, shares issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued License fees License fee License Fee License Fee Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Development and Option Agreement Development And Option Agreement [Member] Development And Option Agreement [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Upfront license fee paid Upfront License Fee Paid Upfront License Fee Paid Gain on extinguishment of note payable Gain on extinguishment of notes payable and accrued interest Gain (Loss) on Extinguishment of Debt Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Business combination shares issued (in usd per share) Business Acquisition, Share Price Stockholders' equity (deficit) Stockholders' Equity Attributable to Parent [Abstract] Note payable Notes Payable, Current Balance Sheet Location [Axis] Balance Sheet Location [Axis] Lease liabilities long-term Operating Lease, Liability, Noncurrent Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Commencement period for stage two upon achievement of stage one Commencement Period For Stage Two Upon Achievement Of Stage One Commencement Period For Stage Two Upon Achievement Of Stage One Licensing Agreements Licensing Agreements [Member] City Area Code City Area Code Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) DARE-LARC1 DARE-LARC1 [Member] DARE-LARC1 Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Other Non Current Assets Other Noncurrent Assets [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Canceled/forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Issuance of common stock in connection with milestone payment Stock Issued During Period, Value, Milestone Payment Stock Issued During Period, Value, Milestone Payment Equity Components [Axis] Equity Components [Axis] Antidilutive Securities Antidilutive Securities [Axis] Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Total current assets Assets, Current Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Sale of Stock Sale of Stock [Domain] Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Increase in number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease) Entity File Number Entity File Number Issuance of common stock from the exercise of warrants Adjustments to Additional Paid in Capital, Warrant Issued Adare Adare Pharmaceuticals [Member] Adare Pharmaceuticals [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Product and Service [Axis] Product and Service [Axis] Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business Proceeds from the exercise of common stock warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Weighted-average fair value of options granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Catalent and MilanaPharm Catalent and MilanaPharm [Member] Catalent and MilanaPharm Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Statement [Line Items] Statement [Line Items] Deferred license revenue Increase (Decrease) in Contract with Customer, Liability Remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Amount authorized under sales agreement Offering Program, Gross Amount Authorized Under Sales Agreement Offering Program, Gross Amount Authorized Under Sales Agreement Counterparty Name [Domain] Counterparty Name [Domain] Entity Address, State or Province Entity Address, State or Province Level 2 Fair Value, Inputs, Level 2 [Member] Type of Adoption [Domain] Accounting Standards Update [Domain] Deferred license revenue Contract with Customer, Liability, Noncurrent Entity Entity [Domain] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Entity Shell Company Entity Shell Company Local Phone Number Local Phone Number Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Certain clinical and regulatory development milestone payments License Agreement Notice Period Of Termination License Agreement Notice Period Of Termination Aggregate net proceeds on sales of shares of common stock Proceeds from Issuance of Common Stock Total assets Assets Expiration Date Class Of Warrant Or Rights Warrants Expiration Date Class of warrant or rights warrants expiration date. Plan Name Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Initial term of license agreement License Agreement, Initial Term License Agreement, Initial Term Percentage of royalty rate Percentage Of Royalty Rate Percentage of royalty rate. Net loss to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Renewal term of operating lease Lessee, Operating Lease, Renewal Term Unamortized costs related to legal, accounting, and other fees Deferred Offering Costs, Unamortized Portion Deferred Offering Costs, Unamortized Portion Contingent consideration, liability Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Cash paid to stockholders' representative Payments to Stockholders' Representative in Business Combination Payments to Stockholders' Representative in Business Combination Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Tax Identification Number Entity Tax Identification Number Subsequent Event [Line Items] Subsequent Event [Line Items] Other receivables Other Receivables, Net, Current Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Loss per common share - diluted (in usd per share) Earnings Per Share, Diluted Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current License agreement termination periodic discontinued sale of product License Agreement Termination Periodic Discontinued Sale Of Product License Agreement Termination Periodic Discontinued Sale Of Product Other non-current assets Increase Decrease In Other Non Current Assets And Deferred Charges Increase decrease in other non-current assets and deferred charges. Project [Axis] Project [Axis] Purchase Agreement Purchase Agreement [Member] Purchase Agreement Upon Signing of Development and Option Agreement Upon Signing Of Development And Option Agreement [Member] Upon Signing Of Development And Option Agreement [Member] Subsequent Events Subsequent Events [Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Accounts payable Accounts Payable, Current Issuance cost on equity paid in common stock Issuance Cost On Equity Paid In Common Stock Issuance Cost On Equity Paid In Common Stock Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Notes payable including accrued interest Notes Payable, Current, Plus Accrued Interest Notes Payable, Current, Plus Accrued Interest Accumulated other comprehensive loss AOCI Attributable to Parent [Member] License fee to be paid upon contingency License Fee, To Be Paid Upon Contingency License Fee, To Be Paid Upon Contingency Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Percentage of rights to inventions by employees under license agreement Percentage Of Rights To Inventions By Employees Under License Agreement Percentage of rights to inventions by employees under license agreement. Business acquisition transaction value Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders' equity. Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stockholders Equity [Table] Stockholders Equity [Table] Stockholders' equity. Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Income Statement Location Income Statement Location [Domain] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Property and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Issuance of common stock in connection with an acquisition (in shares) Stock Issued During Period, Shares, Milestone Payment Stock Issued During Period, Shares, Milestone Payment MilanaPharm MilanaPharm [Member] MilanaPharm [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Net amount payable Milestone Payments, Contingent Amount Payable, Net Milestone Payments, Contingent Amount Payable, Net Related Party Transaction [Domain] Related Party Transaction [Domain] Document Quarterly Report Document Quarterly Report Warrants Expiring on February 15, 2023 Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Upon Completion of Fifty Percent Development Not Later Than Six Months Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Warrants Warrant [Member] Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Stock-based compensation expense Share-based Payment Arrangement, Expense Document Fiscal Period Focus Document Fiscal Period Focus Grant Awards Grant Award [Text Block] Grant Award [Text Block] NICHD NICHD [Member] NICHD Counterparty Name [Axis] Counterparty Name [Axis] Class of Warrant or Right Class of Warrant or Right [Axis] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Current assets Assets, Current [Abstract] Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Leases [Abstract] Entity Central Index Key Entity Central Index Key Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Stock options exercised (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Related Party Related Party [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Summary of Stock Option Activity for Amended 2014 Plan and Related Information Share-based Payment Arrangement, Option, Activity [Table Text Block] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Incremental borrowing rate Lessee, Operating Lease, Discount Rate Obligation to purchase common stock Purchase Obligation Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Estimated fair value of warrants recorded in equity Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] General and administrative General and Administrative Expense [Member] Lincoln Park Lincoln Park [Member] Lincoln Park Expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Class of Stock [Domain] Class of Stock [Domain] Non-cash operating lease cost Non-Cash Lease Expense Non-Cash Lease Expense Entity Address, Postal Zip Code Entity Address, Postal Zip Code Annual percentage increase in outstanding number of common stock Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate. Title of 12(b) Security Title of 12(b) Security Statement [Table] Statement [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Issuance cost on equity line paid in common stock Stock Issued During Period, Value, Consideration For Commitment To Purchase Shares Stock Issued During Period, Value, Consideration For Commitment To Purchase Shares Statistical Measurement Statistical Measurement [Axis] Other receivables Increase (Decrease) in Other Receivables Subsequent Event Subsequent Event [Member] Number of significant performance obligations Number of Significant Performance Obligations Number of Significant Performance Obligations Cover [Abstract] ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Warrant, exercise price, decrease (in usd per share) Warrant, Exercise Price, Decrease Operating lease, right-of-use asset, statement of financial position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Issuance of common stock from the exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Health Care Trust Funds [Axis] Health Care Trust Funds [Axis] Health Care Trust Funds Grant Grant [Member] Non-cash adjustments reconciling net loss to operating cash flows: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type Subsequent Event Type [Axis] Warrants exercised (in shares) Gross Proceeds From Warrants Exercised Gross Proceeds From Warrants Exercised Non-cash lease expenses Operating Lease, Cost Amount awarded for grant Proceeds From Award Of Grant Proceeds From Award Of Grant Payment of additional consideration Payment of Additional Consideration in Business Combination Payment of Additional Consideration in Business Combination Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]